NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Nutriband Inc. (NTRB) Stock Analysis

Nutriband Inc. (NTRB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

NTRB

$6.14

+$0.29 (+4.96%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NTRB with… →

NTRB Key Statistics

As of Oct 21, 2026
Trading
Open
$5.85
Previous Close
$5.85
Day's Range
5.81–6.20
52-Week Range
2.80–9.19
Volume
21.79K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.93
Valuation
Market Cap
$74.64M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
46.14
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.53
Financials (FY)
Revenue (FY)
$2.04M−4.81%
Net Income (FY)
−$8.23M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
12.16M
1-Year Return
−15.60%
Dividend and dates
Avg Volume
66.81K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, NTRB closed at $6.14, −15.60% over 1 year.

Nutriband Inc. (NTRB) has a market capitalization of $74.64M.

In fiscal 2025, NTRB reported revenue of $2.04M.

NTRB Stock Return by Calendar Year

Nutriband Inc. (NTRB) return since Oct 2021: what $10,000 became

1 year
$10,000 $8,440
−15.60%
5 years
$10,000 $12,301
+23.01%
Since Oct 2021
$10,000 $10,701
+7.01%

If you had invested $10,000 in Nutriband Inc. (NTRB) at the close on October 1, 2021, the earliest close on record here, it would have been worth $10,701 at the close on October 21, 2026: +7.01% in total, +1.35% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+35.24%
2025−3.61%
2024+103.02%
2023−35.64%
2022−58.30%
2021 (partial year)+50.67%

As of October 21, 2026.

NTRB Revenue and Earnings by Fiscal Year

FY ends January
Fiscal yearRevenueNet incomeNet margin
2025$2.04M−$8.23M−404.1%
2024$2.14M−$10.48M−489.9%
2023$2.09M−$5.49M−263.0%
2022$2.08M−$4.48M−215.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.04M$566.31K−$8.32M−$8.23M−404.1%
2024$2.14M$743.32K−$6.69M−$10.48M−489.9%
2023$2.09M$862.11K−$4.87M−$5.49M−263.0%
2022$2.08M$750.41K−$4.15M−$4.48M−215.6%

Annual figures as reported, in the company's reporting currency. As of January 31, 2026.

NTRB Valuation vs Biotechnology Median

Median of 608 stocks
MetricNTRBBiotechnology medianvs median
P/S ratio46.1413.303.5x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Nutriband Inc. (NTRB) at $74.64M. The company sits in the Healthcare sector, in the Biotechnology industry.

The 52-week range on file runs from $2.80 to $9.19. The most recent close on file for NTRB is $6.14, dated October 21, 2026. That is +$0.29 (+4.96%) against the previous close. The latest close sits 119.29% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $2.04M. Against the prior fiscal year total of $2.14M, that is a change of −4.81%. The same year closed with a net loss of $8.23M. Earnings per share on a trailing basis come to −0.53.

Across the 4 fiscal years on file, revenue moves from $2.08M in 2022 to $2.04M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 46.14 times revenue. On price-to-sales that is 3.5 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is −15.60%. Across 5 years the annualized return works out at +4.23%. Beta against the wider market is reported at 1.93. Daily returns over the trailing 5 years annualize to a volatility of 125.5%.

Growth & Income

The record shows no dividend for NTRB.

So far in 2026 the total return is +35.24%. Across the complete calendar years on file, 2024 returned +103.02% and 2022 returned −58.30%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Nutriband Inc. (NTRB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Nutriband Inc. NTRB $74.64M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Nutriband Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Nutriband Inc.

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Visit website →